Lung inflammation and injury can quickly turn into acute respiratory distress syndrome (ARDS) in patients with pneumonia, COVID-19 and other conditions.

MiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and ...

Researchers at the University at Buffalo are testing omega-3-based nanomedicine in mice to boost inflammation-resolving ...

New research suggests that thistle, long known as a medicinal plant that supports liver health, may also help prevent acute ...

Polish and US researchers have found a way to stop a destructive form of cell death after it has already begun.

AirCARE1 has received Federal Aviation Administration (FAA) authorization to carry inhaled nitric oxide (iNO), aboard its Learjet 60 aircraft after completing the required clinical, operational, and ...

It's perhaps no surprise that doctors weren't feeling too good about Steven, giving him just a four percent chance of survival, but his sister made it clear that they 'never lost hope' in a previous ...

A 25-year-old woman died after undergoing cesarean delivery at Kota’s JK Lone Hospital on Tuesday, the second maternal death in 24 hours, with the doctors attributing her death to seizures and ...

(Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced ...

We are very pleased with the strong momentum and growing market acceptance in the first full quarter of YARTEMLEA’s commercial launch,” said Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief ...

Added 3 top-rated children's hospitals to QUELIMMUNE- pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI ...

Key Points Interested in Talphera, Inc.? Here are five stocks we like better. NEPHRO-CRRT enrollment reached 75%, with completion expected later in 2026. Talphera anticipates top-line data ...